目的 研究伊曲康唑对全反式维甲酸(ATRA)药动学的影响，探讨联合用药方法，解决ATRA治疗中耐药问题的可能性。方法 将动物按交叉试验方法给药，先后按单用维甲酸和合用维甲酸与伊曲康唑两种方案给药，以高效液相色谱法测定维甲酸血药浓度，研究两种给药方案的药动学差异。结果 维甲酸在动物体内的药动学过程符合单室开放模型，单用及合用的药动学参数cmax分别为(113.83±62.65)，(281.91±75.40) ng·mL-1(P＜0.01);tmax分别为(3.67±0.50)，(2.11±0.60) h(P＜0.01)；MRT分别为(4.34±0.83)，(2.89±0.34) h(P＜0.01)；AUC0～∞分别为(374.9±179.5)，(675.5±212.6) ng·h·mL-10.01＜P＜0.05)；t1/2ke分别为(2.40±0.98)，(1.91±1.26) h(P＞0.05)。结论 合用伊曲康唑可以升高ATRA血药峰浓度和维持有效治疗浓度，提示并用伊曲康唑可能是解决维甲酸耐药的一种方法，值得临床作进一步研究。
Abstract
OBJECTIVE To investigate the effect of itraconazole on the pharmacokinetics of all-trans-retinoic acid (ATRA).METHODS ATRA (10 mg) alone and simutaneously with itraconazole (10 mg+30 mg)were administered orally in a randomized,cross-over way.A reversed-phase high performance liquid chromatographic method was established for the determination of ATRA in serum.RESULTS The pharmacokinetics of ATRA conformed to a one-compartment open model.The main pharmacokinetic parameters after the oral administration alone and combination were as follows:cmax were (113.83±62.65) ng·mL-1 and (281.91±75.40) ng·mL-1(P＜0.01);tmax were (3.67±0.50) h and (2.11±0.60) h(P＜0.01)；MRT were (4.34±0.83) h and (2.89±0.34) h(P＜0.01)；AUC0～∞ were (374.9±179.5) ng·h·mL-1 and (675.5±212.6) ng·h·mL-1(0.01＜P＜0.05)；t1/2ke were (2.40±0.98) h and (1.91±1.26) h(P＞0.05),respectively.CONCLUSION There was significant effect of itraconazole on the pharmacokinetics of ATRA,the cmax and AUC of ATRA were increased by the combination.The use of ATRA in combination with itraconazole merits further investigation.
关键词
伊曲康唑 /
维甲酸 /
药动学 /
药物相互作用
{{custom_keyword}} /
Key words
itraconazole /
all-trans-retinoic acid /
pharmacokinetics /
interaction
{{custom_keyword}} /
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1］Muindi JRF,Frankel SR,Huselton C,et al.Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia［J］.Cancer Res,1992,52:2138.
[2］Muindi JRF,Frankel SR,Miller JrWH,et al.Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations:implication for relapse and retinoid resistance in patients with acute promyelocytic leukemia［J］.Blood,1992,79:299.
[3］Warrell JrRP.Retinoid resistance in acute promyelocytic leukemia:new mechanisms,strategies and implications (editorial:comment)［J］.Blood,1993,82:1949.
[4］余自成，姚帅，郁人海.高效液相色谱法同时检测人血清中全反式及13-顺式维甲酸浓度［J］.药物分析杂志，2000，20：226.
[5］Martini R,Murray M.Participation of P450 3A enzymes in rat hepatic microsomal retinoic acid 4-hydroxylation［J］.Arch Biochem Biophys,1993,303:57.
[6］Roberts ES,Vaz AND,Coon MJ.Role of isozymes of rabbit microsomal cytochrome P-450 in the metabolism of retinoic acid,retinol,and retinal［J］.Mol Pharmacol,1992,41:427.
[7］Leo MA,Lasker JM,Raucy JL,et al.Metabolism of retinol and retinoic acid by human liver cytochrome P450IIC8［J］Arch Biochem Biophys,1989,269:305.
[8］Van Wauwe JP,Coene MC,Goossens J,et al.Ketoconazole inhibits the in vitro and in vivo metabolism of all-trans-retinoic acid［J］.J Pharmacol Exp Ther,1988,245:718.
[9］Maurice M,Pichard L,Daujat M,et al.Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture［J］.FASEB J,1992,6:752.
[10］Schwartz EL,Hallam S,Gallagher RE,et al.Inhibition of all-trans-retinoic acid metabo lism by fluconazole in vitro and in patients with acute promyelocytic leukemia［J］.Biochem Pharmacol,1995,50:923.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
